33 results
6-K
EX-99.1
SNY
Sanofi
25 Apr 24
Sales growth of 6.7% at CER and business EPS(1) of €1.78
10:49am
the 1st adult patient was dosed with this compound)
Planet Care
Q1 2024
Q4 2023
Climate change - Carbon footprint
(CO2 emissions)
55% reduction
6-K
EX-99.1
SNY
Sanofi
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
preparation for clinical study
1 additional asset identified for clinical development
Planet Care
Climate change - Carbon footprint
(CO2 emissions)
55
6-K
EX-99.1
SNY
Sanofi
27 Oct 23
Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
12:39pm
preparation for clinical study
2 external collaboration
contracts with the pediatric ITCC consortium established
Planet Care
Climate change - Carbon
6-K
EX-99.1
SNY
Sanofi
27 Sep 23
Current report (foreign)
6:06am
in delivering first- and best-in-class medicines and vaccines, we double our impact to make our planet healthier.”
Joining forces to go one step further
6-K
EX-99.1
SNY
Sanofi
28 Jul 23
Solid Q2 performance and strong pipeline momentum
3:35pm
is centered around better self-care for healthier people and a healthier planet.
Some of the sustainability highlights from Sanofi Consumer Healthcare North …
2 external collaboration contracts with the pediatric ITCC consortium established
Planet Care
Blister free syringe vaccines
FY 2022
FY 2023
6-K
EX-99.2
693yjywwq8wqvqao
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
6-K
EX-99.1
0hnq d6q4neiut37
27 Apr 23
Strong Q1 growth driven by Specialty Care, Vaccines and CHC
11:39am
6-K
EX-99.2
qn9pvo oq0w1
24 Apr 23
Current report (foreign)
9:55am
6-K
EX-99.1
ncb7sfn9f8g1ar
28 Oct 22
Continued strong growth in Q3 with key regulatory milestones achieved
11:16am
6-K
EX-99.1
zp5o9zf2tr18nesh105
28 Jul 22
Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease
10:12am
6-K
EX-99.2
r7iie
28 Jul 22
Condensed Half-year Consolidated Financial Statements
6:17am
6-K
EX-99.1
4gvbgu8p dp9g0x
8 Jul 22
Sanofi Global Health launches nonprofit Impact® brand for 30 medicines in low-income countries
11:01am
6-K
EX-99.1
w54dxz5b3zvcxh ui
28 Apr 22
Sanofi continues to deliver strong business EPS(1) growth driven by higher sales and improved margins in Q1
12:16pm
6-K
EX-99.2
tdjeyrv
7 Apr 22
If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis
3:13pm
6-K
EX-99.1
zjsiev
15 Mar 22
Sanofi recognized by S&P as one of the most sustainability-committed companies
3:52pm
6-K
EX-99.1
oniq6 sen
28 Oct 21
Q3 2021 sales grew double digit to €10.4 billion (up 10.1%) due to strong growth from Dupixent®, Vaccines and CHC
11:19am
6-K
EX-99.1
4wohaizhyhrpb gro
30 Jul 21
Current report (foreign)
4:01pm
6-K
EX-99.2
gwliab3pnnfq23sk
29 Jul 21
Current report (foreign)
10:48am
6-K
EX-99.1
3z5y ww6krv5ym
29 Jul 21
Sales growth accelerated - Full-year guidance raised
9:52am